<?xml version='1.0' encoding='utf-8'?>
<document id="29112329"><sentence text="In Vitro and In Vivo Investigation of Potential for Complex CYP3A Interaction for PF-00251802 (Dagrocorat), a Novel Dissociated Agonist of the Glucocorticoid Receptor."><entity charOffset="143-157" id="DDI-PubMed.29112329.s1.e0" text="Glucocorticoid" /></sentence><sentence text="The dissociated agonists of the glucocorticoid receptor are a novel class of agents in clinical development for rheumatoid arthritis"><entity charOffset="32-46" id="DDI-PubMed.29112329.s2.e0" text="glucocorticoid" /></sentence><sentence text=" PF-04171327 (fosdagrocorat) is a phosphate ester prodrug of PF-00251802 (dagrocorat), a selective high-affinity partial agonist of the glucocorticoid receptor, which is further metabolized to PF-04015475"><entity charOffset="14-27" id="DDI-PubMed.29112329.s3.e0" text="fosdagrocorat" /><entity charOffset="34-49" id="DDI-PubMed.29112329.s3.e1" text="phosphate ester" /><entity charOffset="136-150" id="DDI-PubMed.29112329.s3.e2" text="glucocorticoid" /><pair ddi="false" e1="DDI-PubMed.29112329.s3.e0" e2="DDI-PubMed.29112329.s3.e0" /><pair ddi="false" e1="DDI-PubMed.29112329.s3.e0" e2="DDI-PubMed.29112329.s3.e1" /><pair ddi="false" e1="DDI-PubMed.29112329.s3.e0" e2="DDI-PubMed.29112329.s3.e2" /><pair ddi="false" e1="DDI-PubMed.29112329.s3.e1" e2="DDI-PubMed.29112329.s3.e1" /><pair ddi="false" e1="DDI-PubMed.29112329.s3.e1" e2="DDI-PubMed.29112329.s3.e2" /></sentence><sentence text=" This study evaluated the cytochrome P450 (CYP)-mediated drug-drug interaction (DDI) potential of PF-00251802 and PF-04015475 in vitro and used model-based prediction approaches to estimate clinical impact" /><sentence text=" PF-00251802 is a reversible inhibitor of several CYPs, but modeling has suggested no clinically relevant interaction" /><sentence text=" PF-00251802 and PF-04015475 are time-dependent inhibitors and inducers of CYP3A in vitro; PF-00251802 is also a time-dependent inhibitor of CYP2D6" /><sentence text=" Model-based prediction suggested the potential for weak inhibition of CYP3A in vivo" /><sentence text=" A clinical DDI study was conducted with midazolam, a sensitive CYP3A substrate"><entity charOffset="41-50" id="DDI-PubMed.29112329.s8.e0" text="midazolam" /></sentence><sentence text=" A phase 1 open-label, multiple-dose study evaluated the effect of PF-04171327 on midazolam pharmacokinetics and safety in 12 healthy volunteers"><entity charOffset="82-91" id="DDI-PubMed.29112329.s9.e0" text="midazolam" /></sentence><sentence text=" Administration of midazolam alone or concomitantly with PF-04171327 resulted in equivalent pharmacokinetic profiles (AUCinf , 21"><entity charOffset="19-28" id="DDI-PubMed.29112329.s10.e0" text="midazolam" /></sentence><sentence text="17 vs 20" /><sentence text="28 ngÂ·h/mL, respectively), indicating that PF-04171327 had no net effect on CYP3A activity in vivo" /><sentence text=" These findings support the further development of PF-00251802 and PF-04171327 as potential treatments for patients with rheumatoid arthritis (NCT00987038)" /><sentence text="" /></document>